CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
CC-486drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02494258
NCT02494258Phase 2Completed
CompareCT.gov

A Phase 2, Open-Label, Single-Arm Rollover Study to Evaluate Long-Term Safety in Subjects Who Participated in Other Celgene Sponsored CC-486 (Oral Azacitidine) Clinical Trials in Hematological Disorders

Celgene·interventional·Posted Jul 10, 2015·Updated Apr 2, 2026

In Brief

A Phase 2 clinical trial evaluating CC-486 for Hematologic Neoplasm and 2 related conditions. Completed, enrolled 5 participants across 4 sites in 2 countries.

Detailed Summary

Rollover study supporting hematological disorder indications from Celgene sponsored CC-486 (oral azacitidine) protocols eligible for participation in the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Neoplasm, Neoplasms, Hematologic Malignancies
CountriesUnited Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 10, 2015
Enrollment StartOct 22, 2015
Primary CompletionApr 14, 2025
TodayJul 2, 2026
Enrollment to primary: 9.5 yearsPosted 11.0 years ago

Interventions

CC-486drug

The subject will continue at the same dose, frequency and schedule used for the last dose of CC-486 given in the preceding CC-486 study. Subjects are allowed to rollover after the last cycle is finished and before the new cycle begins in the parent protocol. There is a 7 day window from End of Study on the parent protocol and when the participant will start Day 1 of the rollover study.